News
MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development
MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced that they have entered into a collaboration to develop human disease models to characterise novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).![Microscoop](/sites/default/files/styles/news_list/public/news/microscope-275984_1920.jpg?itok=IjVbyHtz)
Healthy Working as Part of a Healthy Lifestyle
‘The working environment is a very important aspect of the living environment: about half of the Dutch population is employed’, says Anne van Putten. How does the Ministry of Social Affairs and Employment (SZW) stimulate a healthy working environment and prevent health problems?![healthy](/sites/default/files/styles/news_list/public/news/pexels-daria-shevtsova-1095550%20v3.jpg?itok=c-iA9mnC)
Zeven Consortia over Stamcellen, Genetische Zieken en Embryomodellen van Start
In juni 2021 maakte ZonMw bekend welke 7 consortia zullen starten binnen het programma PSIDER. Met een budget van 3,5 tot 4 miljoen gaan de consortia de komende 5 tot 6 jaar in multidisciplinair verband samenwerken.![Research](/sites/default/files/styles/news_list/public/news/pexels-chokniti-khongchum-2280571.jpg?itok=BQpH4nB_)
Orchard Therapeutics and Pharming Group Announce Collaboration on Therapy for Hereditary Angioedema
Orchard Therapeutics and Pharming Group N.V. announced a strategic collaboration to research, develop, manufacture and commercialise OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.![Lab](/sites/default/files/styles/news_list/public/news/23917_lores.jpg?itok=clU2Ovl-)
MSD Spin-Off Organon Launches in the Netherlands and Worldwide
As a spin-off of US-based MSD, Organon & Co. celebrated its launch as the only global company to focus on women’s health on such an extensive scale. The completion of the spin-off, first announced by MSD in 2020, is good news for women worldwide and for life sciences & health innovation in the Netherlands.![womens health](/sites/default/files/styles/news_list/public/news/pexels-mart-production-7088841.jpg?itok=Y7NybWBH)
En de winnaar is... SARA Robotics!
De winnaar van alweer de derde editie van de Health Impact Accelerator is bekend: SARA Robotics! Het team, bestaande uit Maartje Claassen, Emmy Hendriks, Floor Ruyten, Annabelle Hermans en Evelien Hopman, werd tijdens het Slotevenement op 2 juli uitgeroepen tot winnaar.Cytek Biosciences Moves to Amsterdam Life Sciences District
US-based Cytek Biosciences is moving its regional headquarters for Europe, the Middle East and Africa (EMEA) to the Ada Health & Technology Center in the Amsterdam Life Sciences District. As a specialist in full spectrum flow cytometry, Cytek joins a growing number of innovative companies to settle in the office campus as part of the Netherlands’ life sciences & health ecosystem.![Amsterdam](/sites/default/files/styles/news_list/public/news/pexels-gabriel-guita-4456989.jpg?itok=vx36IG5G)
Lifestyle and Living Living Environment: Continuing the Success-story of Prevention
The story of large-scale preventive interventions and the great health gains they have caused, is an underexposed story. In this interview, Jochen Mierau (University of Groningen) and Hanneke Molema (TNO), tell this story.![Banner](/sites/default/files/styles/news_list/public/news/istockphoto-907930534-612x612.jpg?itok=vN5W9_82)
Lonza and Moderna Expand Collaboration to Produce COVID-19 Vaccines in the Netherlands
Swiss multinational Lonza is strengthening its existing collaboration with US-based Moderna by launching a new COVID-19 Vaccine Moderna production line in the Netherlands. The biotech and pharmaceutical company will now manufacture up to 300 million doses at its site in the Brightlands Campus in Geleen.![Lab](/sites/default/files/styles/news_list/public/news/pexels-polina-tankilevitch-3735747.jpg?itok=0Gyah8d3)
Immunicum: Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine
Immunicum AB announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company’s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment.![Doctor](/sites/default/files/styles/news_list/public/news/pexels-pixabay-40568.jpg?itok=YPnehYxs)